e-learning
resources
ERJ
2015
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Nonsteroidal anti-inflammatory drugs in community-acquired pneumonia
Crawford Emma, Allen Martin, Mustfa Naveed, Stone Helen
Source:
Eur Respir J 2015; 46: 875-876
Journal Issue:
September
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Crawford Emma, Allen Martin, Mustfa Naveed, Stone Helen. Nonsteroidal anti-inflammatory drugs in community-acquired pneumonia. Eur Respir J 2015; 46: 875-876
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Related content which might interest you:
Non-steroidal anti-inflammatory drug use and clinical outcomes of community-acquired pneumonia
Source: International Congress 2018 – Improving the outcomes of community-acquired pneumonia
Year: 2018
Non-steroidal anti-inflammatory drugs may worsen the course of community-acquired pneumonia : A cohort study
Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Year: 2016
Influence of prior nonsteroidal anti-inflammatory steroidal drugs (NSAID) on the presentation and evolution of hospitalized community-acquired pneumonia
Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management
Year: 2015
Macrolides as anti-inflammatory agents in CAP
Source: Eur Respir Monogr 2014; 63: 243-255
Year: 2014
Antipyretic effect of dexamethasone in community-acquired pneumonia
Source: Eur Respir J 2015; 46: 570-573
Year: 2015
Inhaled drugs as risk factors for community-acquired pneumonia
Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools
Year: 2010
Macrolides, mucoactive drugs and adherence for the management of bronchiectasis
Source: Eur Respir J, 51 (1) 1702033; 10.1183/13993003.02033-2017
Year: 2018
Macrolides, mucoactive drugs and adherence for the management of bronchiectasis
Source: Eur Respir J, 51 (1) 1701987; 10.1183/13993003.01987-2017
Year: 2018
Anti-inflammatory therapies in bronchiectasis
Source: Eur Respir Mon 2011; 52: 223-238
Year: 2011
Update on anti-inflammatory therapy in asthma
Source: Research Seminar 2012 - Pulmonary inflammation in paediatric respiratory disease
Year: 2012
Inhaled drugs as risk factors for community-acquired pneumonia
Source: Eur Respir J 2010; 36: 1080-1087
Year: 2010
Novel anti-inflammatory agents
Source: Annual Congress 2009 - Emerging trends in the therapy of COPD
Year: 2009
A randomized trial of AZD7594 a novel non-steroidal anti-inflammatory drug in asthma patients
Source: International Congress 2017 – Novel mechanisms and treatments for asthma
Year: 2017
Azithromycin in the anti-inflammatory treatment of children with asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 167s
Year: 2004
Active monitoring of adverse drug reactions to the use of beta-lactam antibiotics in the treatment of community-acquired pneumonia
Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections
Year: 2020
The risk of community-acquired pneumonia and the use of statins, ACE inhibitors and gastric acid suppressants
Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis
Year: 2008
The etiology and antimicrobial drugs resistance of microorganisms in patients with community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 2s
Year: 2006
Long-term macrolide therapy in chronic inflammatory airway diseases
Source: Eur Respir J 2009; 33: 171-181
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept